CDH2 and lung adenocarcinoma: In this study, compared with the control ones, patients with lung adenocarcinoma showed notably increased expression of MesoMT markers, including N-cadherin (CDH2), α-SMA (ACTA2), and vimentin (VIM) in PMCs, which overlapped with those of MesoMT transcription factors (SNAI1/2 and ZEB1/2) to a great extent.